Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Monoclonal antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Invetx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 19, 2020
Details:
Based on AbCellera's successful delivery on multiple discovery campaigns under the original agreement, the scope of the collaboration has been expanded to include multiple new targets over several years.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IgM antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: IGM Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 24, 2020
Details:
AbCellera will generate panels of antibodies for multiple therapeutic targets identified by IGM using its full-stack and IGM will have the rights to develop and commercialize the novel antibodies resulting from this collaboration.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: OrbiMed
Deal Size: $105.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing May 27, 2020
Details:
With the proceeds of the financing, AbCellera will expand its capacity and invest in technologies that complement and extend its proprietary antibody discovery engine.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Undisclosed
Partner/Sponsor/Collaborator: Bristol-Myers Squibb
Deal Size: $3,065 million Upfront Cash: $65.0 million
Deal Type: Collaboration May 26, 2020
Details:
Companies will leverage Repare’s proprietary, CRISPR-enabled genome-wide synthetic lethal target discovery platform, SNIPRx®, to jointly identify multiple synthetic lethal precision oncology targets for drug candidates.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Human embryonic stem cells
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: NRC IRAP
Deal Size: $0.4 million Upfront Cash: Undisclosed
Deal Type: Funding April 07, 2020
Details:
Support from NRC IRAP will go toward the research and development of a two-step safety switch known as panKiller.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
